Roche 454 Life Sciences and IDT Enter Worldwide Exclusive Agreement for Primer Design and Supply
News Sep 25, 2008
454 Life Sciences, a Roche company, and Integrated DNA Technologies, Inc., Coralville, USA announced that they have entered into an exclusive co-promotional agreement wherein IDT will design, synthesize, and purify the fusion primers required for certain 454 Sequencing applications.
These applications include ultra-deep amplicon sequencing for detection of low-frequency mutations in disease associated genes, and the comprehensive identification and quantification of common and rare variants within a population.
The partnership offers Genome Sequencer FLX System users a solution for primer creation, streamlining workflow and relieving bioinformatics burdens.
IDT's online fusion primer design tool uses a gen-specific data base number or a supplied reference sequence to build appropriate 454 FusionPrimers for targeted DNA regions, including individual exons or all exons from one or more genes.
DNA secondary structure, such as hairpin formation, can affect primer performance. The software takes into account performance metrics of the entire fusion primer rather than simply adding 454 Life Sciences’ universal adaptor sequence to an otherwise standard PCR primer.
In additional to 454 FusionPrimer design, IDT has expertise in high-fidelity synthesis and HPLC purification that can aid the researcher in obtaining the best quality data from their 454 sequencing System.
As the only next generation technology with the ability to sequence more than 400 bases per read, the Genome Sequencer FLX System enables comprehensive analysis, including haplotyping, of complete exons and other genomic regions.
A number of powerful applications are made possible by the system’s long reads and simplified by this new primer design tool. These research applications include ultra deep sequencing for detection of low-frequency somatic mutations in cancer samples, discovery of rare variants in HIV infected individuals, analysis of exon sequences of disease-associated regions, identified by whole genome association studies and sequencing of 16S ribosomal RNA regions to characterize the microbial abundance and diversity in metagenomic samples.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE